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Background: Diabetes is an expensive disease in Argentina as well as worldwide, and its prevalence is continuously
rising affecting the quality of life of people with the disease and their life expectancy. It also imposes a heavy
burden to the national health care budget and on the economy in the form of productivity losses.
Aims: To review and discuss a) the reported evidence on diabetes prevalence, the degree of control, the cost of
care and outcomes, b) available strategies to decrease the health and economic disease burden, and c) how the
disease fits in the Argentinian health care system and policy. Finally, to propose evidence-based policy options to
reduce the burden of diabetes, both from an epidemiological as well as an economic perspective, on the
Argentinian society. The evidence presented is expected to help the local authorities to develop and implement
effective diabetes care programmes.
Methodology: A comprehensive literature review was performed using databases such as MEDLINE, EMBASE and
LILACS (Latin American and Caribbean Health Sciences). Literature published from 1980 to 2011 was included. This
information was complemented with grey literature, including data from national and provincial official sources,
personal communications and contacts with health authorities and diabetes experts in Argentina.
Results: Overall diabetes prevalence increased from 8.4% in 2005 to 9.6% 2009 at national level. In 2009, diabetes
was the seventh leading cause of death with a mortality rate of 19.2 per 100,000 inhabitants, and it accounted for
1,328,802 DALYs lost in the adult population, mainly affecting women aged over fifty. The per capita hospitalisation
cost for people with diabetes was significantly higher than for people without the disease, US$ 1,628 vs. US$ 833 in
2004. Evidence shows that implementation of combined educative interventions improved quality of care and
outcomes, decreased treatment costs and optimised the use of economic resources.
Conclusions: Based on the evidence reviewed, we believe that the implementation of structured health care
programmes including diabetes education at every level, could improve quality of care as well as its clinical,
metabolic and economic outcomes. If implemented across the country, these programmes could decrease the
disease burden and optimise the use of human and economic resources.
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Table 1 Prevalence of cardiovascular risk factors
Variable National risk factor survey
2005 2009
Overweight (BMI> 25 and <30) 34.4% 35.4%
Obesity (BMI = 30) 14.6% 18.0%
Sedentarism/lack of physical exercise 46.2% 54.9%
Hypertension 34.5% 34.8%
Hypercholesterolemia 27.9% 29.1%
Diabetes 8.4% 9.6%
Source: National Survey of Cardiovascular Risk factors – National Ministry
of Health.
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Diabetes is an expensive disease in Argentina as well as
worldwide, and its prevalence is continuously rising [1].
This situation has encouraged us to review published
evidence on diabetes prevalence, control, cost of care
and outcomes, and to discuss how diabetes fits in the
Argentinian health care system and policy. The Argen-
tinian health care system includes three independent
sectors: the public, the social security and the private
(pre-paid) sectors [2]. The public sector is mainly fi-
nanced through taxes and provides universal access to
free health care to nearly 16 million people (mostly un-
employed and low-income population who are not insured
through social security or private sector) through primary
care units and hospitals with different levels of complexity
[2]. It includes different kinds of disease management pro-
grammes for the ambulatory treatment of chronic diseases
with free supply of drugs through public entities; however,
not all chronic diseases are fully covered. Diabetic patients
can access insulin, some oral drugs and a limited number
of strips for self-monitoring blood glucose (SMBG) free
of charge as part of public health insurance. The social se-
curity sector comprises more than 300 institutions that
depend on provincial governments and different trade
unions. They are organised at national and sub-national
level and cover nearly 17 million people. The level of
health coverage is fixed by law in the so-called Mandatory
Health Programme (MHP) [3]. This sector is financed by
a fixed compulsory contribution (a percentage of the sal-
ary) made by both employee and employer (3% and 6%,
respectively). Finally, the private sector is financed through
prepaid medical plans; it covers about 3.2 million people
and operates in a similar manner as the social security sec-
tor. The magnitude of coverage depends on the plan se-
lected by the individual: the lowest-cost plan considers the
MHP as the standard reference for the minimum level of
coverage required [2].
This study aims to review the status of diabetes man-
agement in Argentina, trying to identify the key chal-
lenges that the country needs to address and the
potential strategies available to reduce the socioeco-
nomic disease burden. We hope that this analysis can
help local authorities in Argentina to develop and imple-
ment effective diabetes care programmes with the aim of
reducing the health and socioeconomic burden this dis-
ease continues to inflict to the country.
Methods
We performed a comprehensive literature review in MED-
LINE, EMBASE and LILACS (Latin American and Carib-
bean Health Sciences) for the period 1980–2011, using the
following key words: diabetes in Argentina, diabetes cost
of care, diabetes cost of management, cost of diabetes com-
plications, diabetes health policy. Abstracts - either inEnglish or Spanish - from the identified references were
collected and screened by the authors for inclusion in the
study. Population based publications on diabetes preva-
lence, incidence, social and economic impact of the dis-
ease with careful statistical data analysis were included in
the revision while those related to the issue but having no
these characteristics were excluded. Full papers of the se-
lected abstract were obtained and carefully analysed by the
authors. The literature review was complemented with
personal communications and contacts with national and
provincial health authorities and diabetes experts in
Argentina in an attempt to include unpublished evidence
and policies. The information collected was then reviewed
and summarised independently by the authors and there-
after the selected material was analysed and used to pre-
pare the final manuscript.
Results
Diabetes burden: incidence, prevalence, mortality and
disability-adjusted life years (DALYs)
Estimates of diabetes incidence are not precise in
Argentina. Prevalence values are more reliable and show
an increase from 8.4% to 9.6% between 2005 and 2009 at
national level (Table 1). Earlier estimates showed a
prevalence of 5% in 1987 [4]. Estimates for 2005 and
2009 are based on patient self-reporting during the first
and second National Risk Factor Survey performed by
the National Health Ministry [1].
Both surveys used a four-stage probabilistic sampling
design and the samples were representative of 96% of
the adult population living in urban areas (5,000 inhabi-
tants or more) [1]. Pilot testing of the questionnaire
found a close relationship between direct measurement
of weight, blood pressure, glycaemia and total choles-
terol and the corresponding self-reported data. Ques-
tionnaire validity was not significantly affected by
gender, age or educational level [1,5].
Mortality
Between 1997 and 2006, the crude diabetes mortality
rate rose from 19.6 to 21.3 per 100,000 inhabitants [6].
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seventh cause of death with a crude mortality rate of 19.2
per 100,000 inhabitants and was responsible for 7,701
deaths in the same year; 66% of these deaths corresponded
to people aged 55 years or older, and cardiovascular dis-
ease was the main cause of death [7]. However, we believe
that, as it occurs in many other countries, diabetes mortal-
ity rate is underestimated in Argentina due to inappropri-
ate registration of the disease as a second or third
underlying cause of death.
DALYs
Concerning DALYs, a preliminary analysis carried out by
CENEXA using the methodology developed by Murray
and Lopez [8] showed that in 2005, diabetes alone (with-
out any chronic complication), together with events of
acute myocardial infarction (AMI) and stroke attribut-
able to diabetes, accounted for 1,328,802 DALYs lost in
the adult population; 85% of this burden was ascribed to
disabilities. These results are explained by the chronic
and progressive course of the disease [9,10].
Most of this burden affects women (60%; 793,011
DALYs) and people over 50 years old (52%; 694,694
DALYs). A preliminary sensitivity analysis conducted over
r and K indicated that different scenarios (r = 0%, K = 1;
r = 3%, K = 0; and r = 3%, K = 1) accounted for 90%, 69%
and 60% of the base case recently reported (r = 0%, K = 0),
respectively [9,10].
On the other hand, a study performed in 2005 by na-
tional health authorities using the Global Burden of Dis-
ease (GBD) methodology and including other diseases [11]
showed that diabetes accounted for 128,576 DALYs, where
the years of life lost (YLL) represented 51% of the total
DALYs. However, these results do not match well with the
GBD data reported by CENEXA and other authors, where
disabilities were the main cause of DALYs [11].
According to the National Study of Disease Burden
already mentioned, diabetes was the 9th and 11th cause
of YLL for women and men, respectively. The top five
conditions were different for men and women, but car-
diovascular disease and cancer were the two most com-
mon conditions in both groups. Regarding DALYs,
diabetes occupied the 6th and 7th place in women and
men, respectively [11].
It is not easy to estimate precisely the possible vari-
ation of diabetes burden in Argentina over the past dec-
ade because the available evidence was obtained using
different methodologies, many of which have changed
over time. However, since the first and the second Na-
tional Risk Factor Surveys were performed using the
same methodology, they provide a more strong evidence
base to support an increase in disease prevalence and we
can infer that the diabetes associated burden parallels
that growth.Diabetes treatment and quality of care
There are two different data sources to assess the quality
of diabetes care processes and outcomes in Argentina:
the QUALIDIAB [12,13] and the International Diabetes
Mellitus Practice Study (IDMPS) [14,15]. QUALIDIAB is
a systematic and continuous survey of the quality of care
provided to people with diabetes in different Latin
American countries. It started as an initiative of DOTA
(Declaration of the Americas) and was sustained over
time by CENEXA. IDMPS is an international survey of
quality of care under "real world conditions" which was
implemented and sustained by pharmaceutical manufac-
turer Sanofi-Aventis. QUALIDIAB and IDMPS studies
employ a structured survey form that is randomly pro-
vided to endocrinologists/diabetologists and general prac-
titioners in similar proportion. Both registries include
demographic characteristics, clinical (body mass index
(BMI), blood pressure) and metabolic indicators (HbA1c,
total cholesterol, HDL-cholesterol and triglyceride mea-
surements [TG]), performance of preventive processes
(monitoring of fundus oculi, feet control) and their out-
comes. They also record type of treatment, chronic com-
plications, hospitalisations and coronary risk status for
people with diabetes.
The data recorded showed that 80% of the people
with Type 2 Diabetes Mellitus (T2DM) are overweight/
obese (BMI≥25) [10-13], only 45% of them have HbA1c
levels ≤7%, and 24% have systolic blood pressure (SBP)/
diastolic blood pressure (DBP) ≤130/80 mm Hg. Further-
more, only around 5% of people with T2DM attain these
three therapeutic goals – normal weight (BMI 18.50-24.99),
glycaemic and blood pressure control - simultaneously
(IDMPS third wave in Argentina, unpublished data).
Consequently, more than 66% of this patient population is
at high risk of developing chronic complications.
Regarding pharmacological treatment, the IDMPS data
showed that 91% of patients with Type 1 Diabetes
(T1DM) were treated with insulin and 9% with insulin
plus oral glucose lowering drugs (OGLD). On the other
hand, 66% of patients with T2DM were treated only with
OGLD, 2% with diet and exercise, 10% with insulin and
21% with insulin plus OGLD (Table 2).
Similarly, a study conducted in 43 health centres in
Argentina comprising 1,899 patients with T2DM [16]
showed that pharmacological treatment was used in
84.4% of the diabetic participants in this study. Of the
total 1,899 T2DM patients, 39.7% received one drug,
35.3% two drugs and 9.4% three drugs. Metformin was
the drug most frequently used (67.3%), while 31.9% of
patients received insulin.
Within the group of CVRFs, diabetes has a privi-
leged position because there is a national diabetes law
that regulates the accessibility to care, drugs and strips
for SMBG.
Table 2 Diabetes type of treatment
Treatment T1DM (N=206) T2DM (N=646)
Only OGLD – 65.8
Only Insulin 90.8 10.5
OGLD + Insulin 9.2 21.4
Diet and Exercise – 2.3
OGLD: Oral Glucose Lowering Drugs. Data expressed as percentage.
Source: IDMPS unpublished data.
Table 4 Preventive process performance in the last
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patients’ needs depends on the health sector considered.
There is a clear overload in the public sector, particularly
concerned with the daily number of patients they have
to take care and some deficits in drug and strip provision.
These characteristics are not observed in the social se-
curity and private sectors due to the better adjustment
among patients number, physicians and allocated budget.
Most provinces have adhered to the National Diabetes
Programme (PRONADIA) [17] and are trying to increase
their capacity to cope with the real needs for quality care
and treatment.
Complications
The QUALIDIAB registry shows that the Argentinean dia-
betic population has frequent chronic complications and
poor control of hyperglycaemia and the associated CVRFs
(Table 3). As it occurs in many countries, cardiovascular
diseases are the most prevalent chronic complications
[12,13,18-23]. However, microangiopathic complications
also represent a heavy burden: diabetes is the main cause
of end-stage renal disease, while diabetic retinopathy is
the first cause of non-traumatic blindness in the adult
population [24].Table 3 Prevalence of diabetes chronic complications
according to disease duration
Complication Diabetes duration (years)
0 - 5 6 - 10 11 - 20 =20
Blindness 1.6 2.6 3.8 6.9
AMI 10.1 10.2 16.8 16.1
Stroke 8.2 9.7 10.4 8.1
ESRD 0.3 0.5 1.1 2.6
Amputation 3.8 5.0 9.0 15.7
Postural hypotension 55.9 52.3 50.1 36.5
Angor 29.1 27.1 28.9 24.9
Neuropathy 55.2 61.7 69.0 73.3
Lower limb claudication 25.0 29.8 31.7 36.7
AMI: Acute myocardial infarction. ESRD: End-Stage Renal Disease. Data
expressed as percentage. Source: QUALIDIAB Database 2006.The proportion of patients screened for complications
and their risk-factors in the last 12 months are described
in Table 4.
Although QUALIDIAB and IDMPS have a good qual-
ity data on diabetes control, their representativeness of
the whole Argentinean population is limited due to
small sample size [12,14].
Diabetes costs: available evidence on its magnitude
Hospitalisation is the main component of the total direct
cost per person of diabetes care [19,21,25]. In 2004,
Gagliardino et al. evaluated the characteristics of hospi-
talised patients and inpatient costs in a cohort of social
security sector insurees, with and without diabetes [19]
(Table 5). While diabetes represented 6% of all the hos-
pitalisations recorded, its cost accounted for 10.5% of
the total inpatient cost.
Cardiovascular diseases were the leading cause of hos-
pitalisation in the two groups studied. The average in-
patient cost of a diabetic patient was significantly higher
than that of a non-diabetic patient (US$ 1,628 vs. US$
833). Comparable average duration figures were re-
corded in people with diabetes for acute (6.3 ± 5.2 days)
and chronic (7.9 ± 8.3 days) complications associated to
the disease. However, the average cost per capita of a
complicated diabetes case was significantly higher than
that of a non-complicated diabetes case (US$ 2,096 vs.
US$ 879; P< 0.01).
Cardiac and peripheral vascular events were the most
expensive causes of hospitalisation (US$ 2,476 and US$
2,219, respectively). People with diabetes spent more
days in hospital than those without the disease (7.8 vs.12 months
Parameter T1DM
(N = 2,160)
T2DM
(N = 16,445)
Total
(N = 18,605)
Body weight 99 99 99
Height 89 93 92
Blood pressure 96 99 98
HbA1c 61 40 43
FBG 74 83 82
Creatinine 89 51 56
Total cholesterol 71 74 74
HDL-cholesterol 52 61 60
Triglyceride 58 68 67
Micro-albuminuria 28 8 11
Foot exam 39 55 54
Retina control 60 45 46
FBG: Fasting blood glucose. Data expressed as percentage.
Source: QUALIDIAB Database 2006.
Table 5 Local evidence in cost of diabetes
Study Evidence Cost values*
Olivera et al. (1991) [28] Total costs for absenteeism and early retirement
in a cohort of people with diabetes
US$ 374,000 and US$ 29,929,900, respectively.
Gagliardino et al. (2004) [19] Hospitalization due to cardiovascular disease in
diabetic people vs. non-diabetic people
US$ 1,628 vs. US$ 833
Hospitalization due to acute vs. chronic
complications in diabetic people
US$ 2,096 vs. US$879
Most expensive causes of hospitalization in diabetic
people: cardiac and peripheral vascular events
US$ 2,476 and US$ 2,219, respectively.
Gagliardino et al. (2006) [20] Direct medical cost per capita of a comprehensive
diabetes care programme vs. control group
(without structured programme)
US$ 1,733 vs. US$ 2,429
Caporale et al. (2006) [21] Pre vs. post-hospitalization ambulatory care cost
of people with diabetes over the same period of
time (6 months)
US$ 904 vs. US$ 798
Caporale et al. (2010) [9] Additional net annual per capita cost of simulated
treatments to avoid hospitalization in diabetic people
US$ 400 to US$ 530
Caporale et al. (2011) [26] Incremental costs of a public health care programme
for people with T2DM without complications
AR$ 1,503 to AR$ 1,141
*Cost data are reported without any intertemporal adjustment.
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sive care units (ICUs) (3.2 vs. 0.7; P< 0.05). Finally, the
re-hospitalisation rate of people with diabetes was 5.5
times higher than that of non-diabetic patients (P< 0.01)
and was significantly associated with a history of severe
episodes of acute (odds ratio: 3.61; 95% CI: 1.11–11.70;
P< 0.05) and chronic (odds ratio: 4.26; 95% CI: 1.60–
11.29; P< 0.01) complications.
We have also analysed and compared the ambulatory
care cost of people with diabetes covered by an Argen-
tinean private health insurer during the pre-and post-
hospitalisation period with that from non-hospitalised
ones during the same period [21] (Table 5). Cardiovascu-
lar diseases were the main cause of hospitalisation
(43.1%), with a significantly higher per capita cost com-
pared to any other identified cause (mean ± standard
error (SE): US$ 1,673 ± US$ 297; P< 0.05). The total an-
nual direct cost per capita of hospitalised patients was
higher than that of non-hospitalised ones (US$ 2,908 ±
262 vs. 473 ± 10, respectively; P< 0.01). Further, the
total post-hospitalisation ambulatory care cost was 12%
higher but not significantly different from that of the
pre-hospitalisation period (US$ 904 ± US$ 109 vs. US$
798 ± US$ 15). Related to this issue, Caporale et al.
(2011) have shown, using a simulation model, that attain-
ment of target HbA1c values by the provision of appropri-
ate treatment to people with T2DM could avoid future
hospitalisation events [26] (Table 5). The additional net
annual per capita cost of the simulated treatments ranged
from US$ 400 to US$ 530, thus having a reasonable
cost-consequence rate from a third payer´s perspective.This preventive policy would simultaneously decrease
cardiovascular complications that require high-cost hospi-
talisation, thus reducing spending on diabetes and its
complications. These results together with those obtained
in PROPAT (study described in detail later in this article),
suggest that intensive treatment of hyperglycaemia and
its associated CVRFs may prevent hospitalisation events,
thus providing a more cost-effective option than the
coverage of hospitalisation and post-hospitalisation ambu-
latory care.
On the other hand, using a micro-costing approach with
a probabilistic sensitivity analysis following Monte Carlo
simulation, Caporale et al. estimated the incremental costs
of a health care programme for people with T2DM with-
out complications in two Argentinean provinces, Córdoba
and Misiones, the first characterised by the relatively
higher socioeconomic status of its inhabitants in compari-
son to the second [27]. For the purpose of the study, a
public health payer at sub-national level was chosen, and
the comparator was a province without a diabetes
programme. The estimated incremental annual health care
cost per patient in deterministic terms was AR$ 1,503 and
AR$ 1,141 for Córdoba and Misiones respectively. In both
provinces, the main component of such cost was SMBG
(around 50%), followed by the treatment of hypergly-
caemia, dyslipidaemia and hypertension, while human re-
sources represented the lowest one (<5%). Since SMBG
was the main determinant of treatment costs, its provision
should be carefully regulated to avoid inappropriate use of
resources and inequities when implementing insulin treat-
ment (in T2DM), which would demand more frequent
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mentation of diabetes programmes at the public health
care sub-sector level in provinces/countries with compar-
able socioeconomic and health care settings. It would also
help to optimise resource use.
Regarding productivity costs, Olivera et al. reported
that the absenteeism of the people with diabetes but
without complications was not significantly higher than
the people without the disease (13 vs. 9 days) [28]. Con-
versely, people with diabetes and chronic complications
lost a significantly higher number of working days than
people without complications (106 vs. 13 days). The
study also demonstrated that in the province of Buenos
Aires, people with diabetes retired earlier from their jobs
due to permanent disabilities and all these retirements
represent a lost of 11 working years. The corresponding
costs for absenteeism and early retirement were US$
374,000 and US$ 29,929,900, respectively.
All the cost data we report in this paper were not ad-
justed for inflation. Due to the high levels of volatility
characterising many Latin American economies, this
may influence an inter-study cost comparisons but does
not affect the individual study results here reported.
Effective strategies to reduce diabetes costs
Some effective strategies to reduce the health and cost
burden of diabetes to the Argentinean health system and
society have been already successfully implemented at
the local level. One example is the implementation of a
comprehensive diabetes care programme (PROPAT) in
the social security sector from 1998 to 2000, which led
to significantly improved clinical and biochemical indi-
cators and higher quality of care for people with T2DM
[20]. Additionally, the total annual per capita health care
expenditure (including ambulatory diabetes care, drugs,
laboratory tests and inpatient) was significantly lower in
people in the intervention group than in the control
group (US$ 1,733 vs. US$ 2,429; P< 0.01).
Evidence from a structured group education programme
for people with T2DM implemented simultaneously in ten
Latin American countries (including Argentina), showed
improved quality of health care indicators and a decrease
by 64% of the cost of drug treatment [29,30]. Further, im-
plementation in a primary care setting, of an intervention
that included education of patients and physicians com-
bined with comprehensive health care coverage resulted in
long-term (three years) improvement in clinical, metabolic
and psychological outcomes at the best cost-effectiveness
ratio [31].
These local results seem to suggest that a large scale
implementation of diabetes education programmes at all
levels of care could decrease the current disease burden
and economic cost due to diabetes in Argentina and op-
timise resource use.Health care policy on diabetes
As mentioned before, Argentina has a national programme
for the prevention and control of diabetes (PRONADIA),
created by Law No. 23.753/89 and regulated by PEN De-
cree No. 1271/98 [17]. This Programme attempts to engage
and commit the provinces to develop and implement sub-
national programmes for disease control and treatment. Its
main aim is "to improve the quality and life expectancy of
people with diabetes, prevent or decrease chronic complica-
tions of this disease and ensure the consequent decline of
direct and indirect costs. In order to achieve these aims it
promotes the active implementation of a prevention and
control programme that prioritises appropriate interventions
on hyperglycaemia and the associated CVRFs and its
chronic complications. Its role is to coordinate and provide
technical support for the programming and implementation
of provincial programmes”. Currently all our provinces have
either adopted or adapted the PRONADIA principles, being
supported with their own budget (federal health care sys-
tem). Additionally, the National Health Ministry has also
developed guidelines for the prevention, diagnosis and dia-
betes treatment targets, based on international guidelines
and with the participation of different academic, scientific
and health care organisations [32]. Although the last edition
of the document was in 2009, it has been difficult to assess
the degree of its implementation and use.
In 2010, PRONADIA tried to widely implement the
QUALIDIAB registry (started in 1999 by CENEXA
[12,13]) through the provincial diabetes programmes, to
assess and follow up objectively the quality of care pro-
vided to people with diabetes and other CVRFs. This
system has introduced small changes in the original QUA-
LIDIAB data record in order to use a single data collection
form for all the CVRFs. This new form, that includes the
impaired glucose tolerance and impaired fasting glucose
conditions, is part of a WHO programme to identify
people with CVRFs and their treatment. The data record-
ing sheet includes indicators on processes, clinical and
metabolic outcomes, drug consumption, hospitalisation
events and chronic complications.
As mentioned before, there is a programme for the free
provision of drugs at national level (REMEDIAR); it
supplies metformin, glibenclamide and human insulin to
publicly insured diabetic patients through primary care
units and public hospitals all over the country. Addition-
ally, the Superintendencia de Servicios de Salud is the na-
tional institution that assess the degree of coverage of care
and drug treatment by all institutions of the social security
system as well as prepaid ones, as established in the PRO-
NADIA, thus they have to cover 100% of the cost of insu-
lin and traditional oral hypoglycaemic agents as well as up
to 300 strips for SMBG/year. The free provision of new
drugs and insulin analogues is not automatically granted
and their coverage/provision is under an audit system, i.e.
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essential is its usage.Discussion
The data currently described clearly demonstrate that in
Argentina, diabetes care consumes a large amount of re-
sources due to its high prevalence and its association
with other CVRFs, along with the presence of chronic
complications. These complications increase the cost of
care and exert a negative impact on quality of life of
people with diabetes, but also affect the economy due
to productivity losses and the community because of dis-
ability, premature mortality, increased spending on
health, disability and early retirement benefits, etc.
The negative impact of the development and progres-
sion of chronic complications can be effectively prevented
by tight control of hyperglycaemia and the associated
CVRFs [33-37]. However, the frequent combination of late
diagnosis, inappropriate quality of care provided to people
with diabetes and uneven access to care and treatment
play against the effectiveness and feasibility of secondary
prevention [12,13,18-20,22,25,38-42].
The patients overload affecting the public health sec-
tor also conspires against the provision of effective care
and the consequent prevention of chronic compliac-
tions. Further, in many cases, the patient does not have
100% medication coverage (which is the case for cer-
tain new drugs, but not for human insulin or agents
such as metformin or glibenclamide), and the conse-
quent extra out-of-pocket (OOP) expenditure becomes
an additional burden for the patient. So far however,
we have not been able to objectively measure the real
burden of OOP payments on individuals and any so-
cioeconomic disparities in access it may lead to due to
lack of data.co
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Figure 1 Progression from normal state to diabetes.Together, all the conditions mentioned above can re-
sult in the provision of poor quality care and disparities
in access for people with T2DM. As a consequence,
many patients do not attain the recommended thera-
peutic goals and develop chronic complications with the
negative consequences mentioned above.
When health care planners and authorities analyse pos-
sible solutions to tackle these problems, one of the main
suggestions emerging it the need to increase the health
care budget. Since most developing countries face eco-
nomic constraints, this option appears difficult to imple-
ment. But if such an increase were feasible, it would not
necessarily provide a real solution. In fact, using data from
countries with higher health care budgets than Argentina,
CENEXA has demonstrated that the quality of care pro-
vided was similarly poor in all of them [22]. These findings
thus showed that the size of the health budget is not the
main constraint for delivering good quality diabetes care
and that there is a need to find more efficient interven-
tions to improve health care quality.
Implementation of educational interventions at every
level could be a potentially effective solution. However,
for such intervention to be successful, reluctance of
many health care providers and people with diabetes re-
garding the importance of the active participation of pa-
tients in the control and treatment of their disease, need
to be overcome [43]. Further, the favourable impact of
educational interventions implemented in Argentina in
different health care settings, upon clinical, metabolic,
psychological and economic indicators needs to be pro-
moted [20,29-31]. Adopting this concept, the Argentin-
ean National Health Ministry has implemented a long-
distance diabetes training programme [24] delivered by
the universities of La Plata (Argentina) and Indiana
(USA) to improve the knowledge and skills of general
practitioners around the country.MALITY TO DIABETES
Without
complications
2100
(2.4x)
With
complications
3400
(3.9x)
Figure 2 Quality of care synergy.
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voted to improving the quality of care of people with
diabetes and secondary prevention, the results so far ob-
tained were really poor. Even though diabetes primary
prevention has been effectively achieved in people at
high risk of developing the disease in different health
systems and in different ethnic populations by adopting
a healthier life style [44], this approach has not been
tested in Argentina. Consequently, CENEXA is actively
working in this direction validating several question-
naires suitable for the identification of populations at
high risk of developing diabetes [45,46], and organising a
multi-sector diabetes primary prevention pilot study in
three cities from the province of Buenos Aires to be
launched in 2013.Recommendations
How do we envisage the close future activities and the es-
tablishment of diabetes health care priorities in Argentina?
We did not currently identify any effective long-term
programme directly related to either primary or secondary
diabetes prevention. We envisage that an improvement
in diabetes outcomes in Argentina would require a set of
coordinated strategies able to prevent both the transition
rate from glucose intolerance to diabetes for people at
high risk of developing diabetes (primary prevention)
and to prevent the development and progression of
chronic diabetes complications (secondary prevention),
thus decreasing the high social and economic cost of the
disease (Figure 1).
Such strategies should be mainly based on education
programmes implemented at every level of the health
care system, including health providers and people with
diabetes as well as focussing on improving access to care
and treatment (Figure 2).In brief, we strongly believe that in Argentina the bur-
den of diabetes can be overcome using the approach pre-
sented in Figure 2, i.e., implementing education strategies
at the level of health care providers and people with
diabetes, and also at health care management level
(those responsible for health care programme organisa-
tion and implementation). A nationwide education
programme must be implemented together with a con-
tinuous evaluation programme to record successful re-
sults and failures that can allow the introduction of
changes to optimise outcomes. The evaluation should
include not only clinical, metabolic and satisfaction in-
dicators, but also appropriate economic indicators (e.g.
direct and indirect costs). The latter can serve to opti-
mise resource allocation based on real needs rather
than on transient political demands and pressures.
To increase the effectiveness of the education pro-
gramme, its design and development should include all
the sectors involved in disease management (health
care authorities, health care organisations and providers
as well as people with diabetes). The public education
sector should also be included, since adoption of healthy
life style habits must start from an early age, preferably
during primary school, when children develop their
future habits.
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